MA43825A - Schémas posologiques pour le traitement d'infections fongiques - Google Patents

Schémas posologiques pour le traitement d'infections fongiques

Info

Publication number
MA43825A
MA43825A MA043825A MA43825A MA43825A MA 43825 A MA43825 A MA 43825A MA 043825 A MA043825 A MA 043825A MA 43825 A MA43825 A MA 43825A MA 43825 A MA43825 A MA 43825A
Authority
MA
Morocco
Prior art keywords
treatment
fungal infections
dosage schedules
schedules
dosage
Prior art date
Application number
MA043825A
Other languages
English (en)
Inventor
Kenneth Bartizal
Paul Daruwala
Jeffrey Brian Locke
Voon Ong
Taylor Sandison
Dirk Thye
Original Assignee
Cidara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics Inc filed Critical Cidara Therapeutics Inc
Publication of MA43825A publication Critical patent/MA43825A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043825A 2016-03-16 2017-03-15 Schémas posologiques pour le traitement d'infections fongiques MA43825A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662309211P 2016-03-16 2016-03-16
US201662350591P 2016-06-15 2016-06-15
US201662415928P 2016-11-01 2016-11-01
US201662418727P 2016-11-07 2016-11-07
US201662419076P 2016-11-08 2016-11-08
US201662436716P 2016-12-20 2016-12-20

Publications (1)

Publication Number Publication Date
MA43825A true MA43825A (fr) 2021-04-07

Family

ID=59850952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043825A MA43825A (fr) 2016-03-16 2017-03-15 Schémas posologiques pour le traitement d'infections fongiques

Country Status (8)

Country Link
US (2) US11712459B2 (fr)
EP (2) EP3430400B1 (fr)
JP (3) JP7224916B2 (fr)
CN (1) CN109154603A (fr)
CA (1) CA3017485A1 (fr)
ES (1) ES2955711T3 (fr)
MA (1) MA43825A (fr)
WO (1) WO2017161016A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2865791C (fr) 2011-03-03 2019-10-08 Cidara Therapeutics, Inc. Agents antifongiques et leurs utilisations
SI3677252T1 (sl) 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
US10369188B2 (en) 2016-01-08 2019-08-06 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
JP7224916B2 (ja) 2016-03-16 2023-02-20 シダラ セラピューティクス インコーポレーテッド 真菌感染の処置のための投薬レジメン
MA49576A (fr) 2017-07-12 2021-04-07 Cidara Therapeutics Inc Compositions et méthodes pour le traitement d'infections fongiques
EP3806882A4 (fr) 2018-06-15 2022-03-23 Cidara Therapeutics, Inc. Synthèse d'un agent antifongique d'échinocandine
US12060439B2 (en) 2018-10-25 2024-08-13 Napp Pharmaceutical Group Limited Polymorph of echinocandin antifungal agent
MX2021013899A (es) * 2019-05-16 2022-02-10 Scynexis Inc Agentes antifungicos para la descolinizacion de candida auris.

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US6030944A (en) 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
AU674233B2 (en) 1993-05-04 1996-12-12 Merck & Co., Inc. Cyclohexapeptidyl aminoalkyl ethers
US5541160A (en) 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
PT805685E (pt) 1995-01-26 2002-02-28 Merck & Co Inc Novos ciclo-hexapeptideos anti-fungicos
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
AR006598A1 (es) 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
US6069126A (en) 1996-09-12 2000-05-30 Merck & Co., Inc. Antifungal combination therapy
ATE338059T1 (de) 1998-12-09 2006-09-15 Lilly Co Eli Reinigung von echinocandin cyclopeptiden
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN1345230A (zh) 1999-03-03 2002-04-17 伊莱利利公司 口服ecb药物制剂和药物组合物的制备方法
DK1582204T3 (da) 1999-03-03 2013-11-04 Lilly Co Eli Echinocandin-farmaceutiske formuleringer, der indeholder miceldannende overfladeaktive stoffer
US6309622B1 (en) 1999-03-26 2001-10-30 Protech Professional Products, Inc. Antimicrobial denture cleansing compositions
KR20010108469A (ko) 1999-04-16 2001-12-07 후지야마 아키라 항진균 조성물
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
WO2005014777A2 (fr) 2002-10-16 2005-02-17 Board Of Regents, The University Of Texas System Procedes et compositions pour augmenter l'efficacite de substances actives d'un point de vue biologique
US6913759B2 (en) 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
EP1654036B1 (fr) 2003-07-22 2007-12-26 Theravance, Inc. Utilisation d'un agent antifongique a base d'echinocandines conjointement avec un agent antibacterien glycopeptidique
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
JP5319281B2 (ja) 2005-07-26 2013-10-16 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー エキノカンジン系薬物に対する耐性の分析法並びに同分析法のためのオリゴヌクレオチド・セット及び試薬キット
WO2007113386A1 (fr) 2006-03-31 2007-10-11 Karyon-Ctt Ltd Conjugués peptidiques
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20090238867A1 (en) 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
AU2010217190B2 (en) 2009-02-25 2012-10-25 Mayne Pharma Llc Topical foam composition
CN102421790A (zh) 2009-05-07 2012-04-18 帝斯曼知识产权资产管理有限公司 制备环肽的方法
SI2470168T1 (en) 2009-08-26 2018-05-31 Bioelectron Technology Corporation Procedures for the prevention and treatment of brain ischemia
US20120190613A1 (en) 2009-08-27 2012-07-26 James Jr Kenneth Duke Echinocandin derivatives
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
CA2865791C (fr) * 2011-03-03 2019-10-08 Cidara Therapeutics, Inc. Agents antifongiques et leurs utilisations
WO2013017691A1 (fr) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Inhibiteurs de cahgtlp destinés à être utilisés dans le traitement de la candidiase
US8829053B2 (en) 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
SI3677252T1 (sl) 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
CN102766198A (zh) 2012-05-04 2012-11-07 中国人民解放军第二军医大学 一种糖肽类抗真菌化合物及其制备方法与应用
US20150320675A1 (en) 2013-01-18 2015-11-12 University Of Utah Research Foundation Modified Release Osmotic Pump for PH-Responsive Drug Delivery
WO2014124504A1 (fr) 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions et méthodes de traitement de biofilms
US9919055B2 (en) 2013-03-15 2018-03-20 Arizona Board Of Regents On Behalf Of Arizona State University Sugar-linker-drug conjugates
AU2014262127B2 (en) * 2013-05-01 2019-05-02 Neoculi Pty Ltd Methods for treating bacterial infections
US20160213742A1 (en) 2013-09-04 2016-07-28 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2017049102A1 (fr) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Méthodes de traitement d'infections fongiques
WO2017049105A1 (fr) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations pour le traitement d'infections fongiques
US10369188B2 (en) 2016-01-08 2019-08-06 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
JP7224916B2 (ja) 2016-03-16 2023-02-20 シダラ セラピューティクス インコーポレーテッド 真菌感染の処置のための投薬レジメン
WO2018085200A1 (fr) 2016-11-01 2018-05-11 Cidara Therapeutics, Inc. Méthodes à dose unique pour la prévention et le traitement d'infections fongiques
WO2018102407A1 (fr) 2016-11-29 2018-06-07 Cidara Therapeutics, Inc Procédés de prévention d'infections fongiques
MA47437A (fr) 2017-01-31 2019-12-11 Cidara Therapeutics Inc Procédés de traitement d'infections fongiques
WO2018187574A1 (fr) 2017-04-05 2018-10-11 Cidara Therapeutics, Inc. Compositions et procédés de traitement d'infections fongiques
WO2018191692A1 (fr) 2017-04-14 2018-10-18 Cidara Therapeutics, Inc. Procédés de traitement d'infections fongiques
MA49576A (fr) 2017-07-12 2021-04-07 Cidara Therapeutics Inc Compositions et méthodes pour le traitement d'infections fongiques
AU2018311375A1 (en) 2017-08-03 2020-03-12 Napp Pharmaceutical Group Limited Methods for preventing and treating intra-abdominal candidiasis
EP3806882A4 (fr) 2018-06-15 2022-03-23 Cidara Therapeutics, Inc. Synthèse d'un agent antifongique d'échinocandine

Also Published As

Publication number Publication date
WO2017161016A1 (fr) 2017-09-21
EP3430400A4 (fr) 2019-10-30
CA3017485A1 (fr) 2017-09-21
EP3430400B1 (fr) 2023-06-21
JP2019511496A (ja) 2019-04-25
EP3430400A1 (fr) 2019-01-23
JP7224916B2 (ja) 2023-02-20
CN109154603A (zh) 2019-01-04
ES2955711T3 (es) 2023-12-05
US20240108684A1 (en) 2024-04-04
JP2022169599A (ja) 2022-11-09
US11712459B2 (en) 2023-08-01
US20190216885A1 (en) 2019-07-18
EP4268896A3 (fr) 2024-01-03
JP7322259B2 (ja) 2023-08-07
EP4268896A2 (fr) 2023-11-01
JP2023139211A (ja) 2023-10-03

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3651801A4 (fr) Compositions et méthodes pour le traitement d'infections fongiques
EP3495118A4 (fr) Composition d'agent de traitement pour précurseur d'objet tridimensionnel